Industry Spotlight

Actinogen Medical starts Phase II trial for Alzheimer’s therapy

18 May 2017 via Biotech Dispatch: A promising areas of Alzheimer’s disease drug research has reached a new milestone, with the recruitment and treatment of the first patient in a Phase II clinical trial of Actinogen Medical’s cortisol-blocking drug Xanamem.

The patient was treated at the Central Coast Neurosciences Research site in New South Wales and is part of a trial that will enrol 174 patients at 20 sites across Australia, the UK and US.

Read more in Biotech Dispatch.